A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

Summary

Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess adverse events, change in disease activity, and how oral emraclidine moves through the body in adult participants with schizophrenia Emraclidine is an investigational drug being developed for the treatment of schizophrenia. Participants are placed in one of two parts, Part A or Part B, where each group will receive a different treatment. Participants will receive either oral emraclidine or placebo.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Schizophrenia

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 65 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

AbbVie

Last updated on ClinicalTrials.gov

September 15, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites